BR112019002461A2 - regime de dosagem para tratamento de tumores sólidos - Google Patents

regime de dosagem para tratamento de tumores sólidos

Info

Publication number
BR112019002461A2
BR112019002461A2 BR112019002461A BR112019002461A BR112019002461A2 BR 112019002461 A2 BR112019002461 A2 BR 112019002461A2 BR 112019002461 A BR112019002461 A BR 112019002461A BR 112019002461 A BR112019002461 A BR 112019002461A BR 112019002461 A2 BR112019002461 A2 BR 112019002461A2
Authority
BR
Brazil
Prior art keywords
solid tumor
dosage regimen
dose
tumor treatment
oxo
Prior art date
Application number
BR112019002461A
Other languages
English (en)
Inventor
Soek Mun Yuen Eunice
Adnane Benhadji Karim
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112019002461A2 publication Critical patent/BR112019002461A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

é fornecido um regime de dosagem que compreende administrar 4,4,4-trifluoro-n-[(1s)-2-[[(7s)-5-(2-hidroxietil)-6-oxo-7h-pirido [2,3-d] [3] benzazepin-7-il]amino]-1-metil-2-oxo-etil]butanamida, ou um sal farmaceuticamente aceitável ou hidrato do mesmo, para tratar um câncer de tumor sólido a uma dose de ataque especificada durante um período definido de doses seguida por uma dose de manutenção e administrando, opcionalmente, um corticosteroide durante a administração da dose de ataque.
BR112019002461A 2016-08-31 2017-08-24 regime de dosagem para tratamento de tumores sólidos BR112019002461A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662381911P 2016-08-31 2016-08-31
PCT/US2017/048308 WO2018044662A1 (en) 2016-08-31 2017-08-24 Dosage regimen for treatment of solid tumors

Publications (1)

Publication Number Publication Date
BR112019002461A2 true BR112019002461A2 (pt) 2019-05-14

Family

ID=59772787

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019002461A BR112019002461A2 (pt) 2016-08-31 2017-08-24 regime de dosagem para tratamento de tumores sólidos

Country Status (13)

Country Link
US (1) US20190209581A1 (pt)
EP (1) EP3506905B1 (pt)
JP (2) JP2019526632A (pt)
KR (1) KR102512899B1 (pt)
CN (2) CN109562114A (pt)
AU (1) AU2017321011B2 (pt)
BR (1) BR112019002461A2 (pt)
CA (1) CA3035616A1 (pt)
IL (2) IL305136A (pt)
MA (1) MA46086A (pt)
MX (1) MX2019002066A (pt)
SG (2) SG10202107832UA (pt)
WO (1) WO2018044662A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
JP6911047B2 (ja) 2016-04-12 2021-07-28 イーライ リリー アンド カンパニー がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法
US11564929B2 (en) 2016-04-12 2023-01-31 Eli Lilly And Company Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer
MX2018013941A (es) 2016-05-20 2019-03-21 Lilly Co Eli Terapia de combinacion con inhibidores de notch y pd-1 o pd-l1.
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
EP4269594A3 (en) 2017-02-17 2023-12-20 Fred Hutchinson Cancer Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US46206A (en) 1865-02-07 Improved vessel for holding petroleum
US8633179B2 (en) * 2007-03-13 2014-01-21 The Trustees Of Columbia University In The City Of New York Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids
EP3574914B1 (en) * 2007-11-13 2021-12-29 ViroPharma Biologics LLC Corticosteroid compositions
JO3148B1 (ar) 2011-07-27 2017-09-20 Lilly Co Eli مركب مثبط لإشارات مسار notch
EP3166627A1 (en) * 2014-07-11 2017-05-17 Genentech, Inc. Notch pathway inhibition
TWI609687B (zh) * 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療

Also Published As

Publication number Publication date
US20190209581A1 (en) 2019-07-11
EP3506905B1 (en) 2024-03-20
AU2017321011A1 (en) 2019-02-21
SG11201901325UA (en) 2019-03-28
KR102512899B1 (ko) 2023-03-23
WO2018044662A1 (en) 2018-03-08
CN116473978A (zh) 2023-07-25
MX2019002066A (es) 2019-06-03
IL264924A (pt) 2019-04-30
CA3035616A1 (en) 2018-03-08
EP3506905A1 (en) 2019-07-10
IL264924B1 (en) 2023-09-01
SG10202107832UA (en) 2021-09-29
KR20190042591A (ko) 2019-04-24
JP2019526632A (ja) 2019-09-19
AU2017321011B2 (en) 2023-08-03
JP2023052108A (ja) 2023-04-11
IL305136A (en) 2023-10-01
IL264924B2 (en) 2024-01-01
CN109562114A (zh) 2019-04-02
MA46086A (fr) 2019-07-10

Similar Documents

Publication Publication Date Title
BR112019002461A2 (pt) regime de dosagem para tratamento de tumores sólidos
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
MX2019012884A (es) Terapia de combinacion.
MX2020002150A (es) Terapia de combinación para el tratamiento del cáncer.
EP3970712A3 (en) Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof
BR112018011266A2 (pt) ?composição farmacêutica, recipiente vedado, inalador dosimetrado, e, métodos para tratar um paciente que sofre ou é propenso a sofrer de um distúrbio respiratório e para estabilizar uma composição farmacêutica?
BR112019002730A2 (pt) acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12021550047A1 (en) USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS
BR112017006272A2 (pt) composição farmacêutica para tratar colite ulcerativa.
BR112021006318A2 (pt) terapia de combinação para o tratamento de câncer
MX2019001467A (es) Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer.
BR112019002945A2 (pt) terapia de combinação para o tratamento de câncer pancreático
BR112017001695A2 (pt) terapia de combinação
BR112015012497A2 (pt) combinações farmacêuticas
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
BR112018068784A2 (pt) método para o tratamento de leucemia
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
BR112018002433A2 (pt) composição farmacêutica para tratamento da enxaqueca
WO2014115859A3 (ja) 分子標的併用腫瘍治療・予防薬
NZ760033A (en) Methods to treat opioid use disorder
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
WO2020053664A8 (en) Combination therapy for the treatment of estrogen-receptor positive breast cancer
IL283422A (en) Methods of treating or preventing asthma by adding an IL-4R antagonist

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]